Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2025
Reporting Period: The filing announces financial results and operational updates for the three months ended March 31, 2025.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the specific financial data but does not list the actual figures within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text; contained in the attached press release.
- Debt and Liquidity: Not provided in the filing text; contained in the attached press release.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It serves only to notify investors that such results have been issued via a press release.
Guidance, Outlook, and Management Commentary
Operational Update: The Company provided an update on operations for the three months ended March 31, 2025, as detailed in the attached press release.
Corporate Presentation: On May 14, 2025, the Company updated its corporate presentation slide deck (Exhibit 99.2), which may contain forward-looking statements or strategic outlooks.
Legal Disclaimer: The information in Item 2.02 and the attached exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2025 revenue, net loss, cash burn, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline milestones, and capital requirements.
- Verify the Company's cash runway and any recent financing activities mentioned in the press release.
- Confirm the status of the Company's emerging growth company status and any related accounting election changes.